Get the Stockscreener App
53.50
3.10%
1.61
Verona Pharma Plc Adr stock is traded at $53.50, with a volume of 1.54M.
It is up +3.10% in the last 24 hours and up +27.32% over the past month.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
See More
Previous Close:
$51.89
Open:
$51.89
24h Volume:
1.54M
Relative Volume:
1.37
Market Cap:
$4.38B
Revenue:
-
Net Income/Loss:
$-153.72M
P/E Ratio:
-26.75
EPS:
-2
Net Cash Flow:
$-103.81M
1W Performance:
+10.45%
1M Performance:
+27.32%
6M Performance:
+133.12%
1Y Performance:
+211.59%
1-Day Range:
$50.86
$54.00
1-Week Range:
$48.50
$55.42
52-Week Range:
$11.39
$55.42
Verona Pharma Plc Adr Stock (VRNA) Company Profile
Name
Verona Pharma Plc Adr
Sector
Industry
Phone
011-44-0-2032834200
Address
3 MORE LONDON RIVERSIDE, LONDON
Compare VRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
53.50 | 4.38B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Oct-03-24 | Initiated | Wells Fargo | Overweight |
| May-22-23 | Resumed | Jefferies | Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-26-22 | Initiated | Piper Sandler | Overweight |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Jefferies | Buy |
| Aug-10-20 | Initiated | Canaccord Genuity | Buy |
| Apr-18-19 | Initiated | BTIG Research | Buy |
View All
Verona Pharma Plc Adr Stock (VRNA) Latest News
Bronchiectasis Market to Show Positive Growth at a CAGR of 13.7% by 2034 | DelveInsight - GlobeNewswire Inc.
Looking For A Top Momentum Pick? Why Valley National Bancorp (NASDAQ: VLY) Is A Great Choice - Stocks Register
Hertz Global Holdings Inc (NASDAQ: HTZ): Overvalued Compared To Others? - Stocks Register
Verona Pharma Plc ADR (VRNA) Outlook: Looking Back For Insights - Stocks Register
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week - Yahoo! Voices
Verona Pharma stock target increased, keeps buy on Q4 sales By Investing.com - Investing.com South Africa
Verona Pharma stock soars to all-time high of $49.05 - Investing.com India
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Verona Pharma stock soars to all-time high of $43.76 - Investing.com
Verona Pharma CFO Mark Hahn sells shares worth $4.4 million - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $4.36 million - Investing.com
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 - Investing.com India
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 By Investing.com - Investing.com South Africa
Verona Pharma CEO David Zaccardelli sells shares worth $627,233 - Investing.com
Verona Pharma CFO sells shares totaling $12,000 - Investing.com India
Verona Pharma's chief medical officer sells $1.18 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $8,000 - Investing.com
Verona Pharma director David Ebsworth buys $88,800 in shares - Investing.com India
Verona Pharma director Christina Ackermann acquires $198,385 in shares - Investing.com
Verona Pharma CFO Mark Hahn sells shares worth $568,386 - Investing.com
Verona Pharma CEO David Zaccardelli sells $618,657 in shares - Investing.com
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre By Investing.com - Investing.com Nigeria
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre - Investing.com India
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday - Investing.com Nigeria
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday By Investing.com - Investing.com South Africa
Verona Pharma ADR earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Verona Pharma CFO Mark Hahn sells shares worth $632,760 - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $633,895 - Investing.com India
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
5 Biotech Stocks Likely To Outperform As Industry Prospects Look Bright - Barchart
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million - Investing.com India
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
Market Insights: Verona Pharma Plc ADR (VRNA)’s Notable Drop of -0.55, Closing at 34.07 - The Dwinnex
Verona Pharma Plc ADR [VRNA] Insider Activity: An Update for Investors - Knox Daily
Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily
Verona Pharma Plc ADR (VRNA) stock: A year of ups and downs - US Post News
VRNA Shares Experience Decline in Value - Knox Daily
Financial Metrics Exploration: Understanding Verona Pharma Plc ADR (VRNA) Through Ratios - The Dwinnex
A stock that deserves closer examination: Verona Pharma Plc ADR (VRNA) - US Post News
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Wells Fargo gives an Overweight recommendation for Verona Pharma Plc ADR (VRNA) - Knox Daily
Verona Pharma Plc ADR’s (NASDAQ: VRNA) Stock Forecast: Increase To $38 In A Year - Stocks Register
Prepare Yourself for Liftoff: Verona Pharma Plc ADR (VRNA) - SETE News
Verona Pharma Plc ADR [VRNA] stock for 2,254,320 USD was sold by ZACCARDELLI DAVID - Knox Daily
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - Yahoo Finance
Cactus Inc [WHD] Records 50-Day SMA of $59.34 - Knox Daily
Verona Pharma stock soars to all-time high of $30.76 By Investing.com - Investing.com South Africa
Piper Sandler maintains Overweight rating on Verona Pharma shares By Investing.com - Investing.com South Africa
Verona Pharma Plc Adr Stock (VRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):